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Introduction
 Combined chemotherapy for head and neck cancers 
has exhibited insufﬁ cient clinical outcomes, particularly 
for salivary gland adenocarcinoma (SGA) as compared 
with oral squamous cell carcinoma (SCC).  Various 
mechanisms are involved in the drug resistance of can-
cer cells.  One mechanism is the multidrug resistance 
(MDR) phenomenon caused by expression of ATP bind-
ing cassette (ABC) transporter in cancer cells.  The ABC 
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Abstract : The aim of the present study was to clarify whether ATP binding cassette transporters are refrac-
tory factors in head and neck cancer chemotherapy.  For in vitro and in vivo chemotherapeutic studies, we em-
ployed a human salivary gland adenocarcinoma cell line (HSY) and a human oral squamous cell carcinoma 
cell line (SCCSK) with vincristine (VCR) at clinically equivalent doses.  Western blot analysis, reverse tran-
scription-polymerase chain reaction, in vivo evaluation in xenograft models inoculated with cultured carcino-
ma cell line and drug efﬂ ux analysis were performed.  VCR-treated SCCSK and HSY cells, as well as xeno-
grafted SCCSK and HSY cells in tumor-bearing nude mice, were found to express MDR1/ABCB1 and MRP1/ 
ABCC1.  In addition to MDR1 and MRP1 mRNA, HSY/VCR and its cloned cells expressed MRP7/ABCC10 
mRNA, but SCCSK/VCR did not express MRP7.  Furthermore, drug resistance to VCR and docetaxel de-
creased in HSY/VCR in the presence of a competitive MRP7 inhibitor, 17-beta-estradiol-(17-beta-D-glucuro-
nide).  These results indicate that MDR1 and MRP1 expression are refractory factors in head and neck cancer 
chemotherapy and suggest that induction of MRP7 expression is involved in drug resistance in salivary gland 
adenocarcinomas.
Key words : multidrug resistance, squamous cell carcinoma, salivary gland cell adenocarcinoma, ABC trans-
porter, MDR1, MRP1, MRP7
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transporter is responsible for active efﬂ ux of anticancer 
drugs out of resistant cells, resulting in signiﬁ cantly de-
creased intracellular drug accumulation and efﬁ cacy1.
 Investigations into ABC transporters have provided 
important insights into the cellular resistance mecha-
nisms associated with anticancer drugs. Some of the 
functional properties of the ABC transporters MDR1/
ABCB1, multidrug resistance-associated proteins 
(MRPs) 1-6/ABCC1-6 and MRP7/ABCC10 have been 
characterized2,3. MRP1, MRP2 (cMOAT) and MRP3 are 
MgATP-energized transporters of glutathione S-conju-
gates, such as leukotriene C4 (LTC4) and S-(2,4-
dinitrophenyl)glutathione4–9.  MRP1, which is widely 
expressed and localized at the basolateral surfaces10,11, 
is distinguished from MRP2 and MRP3 by its higher af-
ﬁ nity for LTC4.  This reﬂ ects the speciﬁ c role that 
MRP1 plays in mediating immune responses involving 
the cellular export of cystinyl leukotriene12–14.  In con-
trast, MRP2 is primarily expressed at the canalicular 
(apical) surfaces of hepatocytes, where it functions in 
the extrusion of endogenous organic anions, such as bili-
rubin glucuronide and certain anticancer agents, and in 
the provision of the biliary ﬂ uid constituent glutathi-
one14.  MRP3 mediates the transport of monoanionic 
bile acids8,15. 
 MRP4 and MRP5 have the capacity to mediate the 
transport of cyclic nucleotides ; this capacity implicates 
the two pumps in the regulation of intracellular levels 
of second messengers and in the extrusion of cAMP in-
volved in intercellular signaling16–18.  Due to their capac-
ity for transporting cyclic nucleotides, MRP4 and MRP5 
are able to confer resistance against certain antiviral 
and anticancer nucleotide analogs, but are apparently 
unable to extrude "natural" agents19–22.  MRP6, a main 
factor in pseudoxanthoma elasticum23, is capable of 
transporting glutathione conjugates24. However, the 
physiological transport substrate involved in the patho-
genesis of pseudoxanthoma elasticum is unknown. 
MRP7 was recently analyzed and found to catalyze the 
MgATP-energized transport of 17-beta-estradiol-(17-be-
ta-D-glucuronide) (E217βG)25.  The expression of these 
ABC transporters may also contribute to MDR in head 
and neck cancers, but the relationship between MDR 
and the ABC transporters is not fully understood.
 To investigate the role of ABC transporters in MDR in 
head and neck cancers, we studied a human SCC cell 
line (SCCSK) and a human SGA cell line (HSY) origi-
nating from the parotid glands.  We evaluated MDR 
gene expression and gene product levels in in vitro and 
in vivo chemotherapeutic models using an MDR-related 
drug (vincristine ; VCR) at clinically equivalent doses 
(CED).  Furthermore, we discuss the differences be-
tween SCC and SGA with regard to acquisition of the 
ABC transporter-mediated MDR phenotype.
Materials and Methods
1. Cell culture of head and neck cancer cell lines
 A human SCC cell line (SCCSK)26, a human SGA cell 
line (HSY)27, and an MDR1- and MRP1-inducible cell 
line (HL-60) were maintained in Dulbecco's modiﬁ ed 
Eagle's medium (DMEM) supplemented with 4 mM 
L-glutamine, 44 mM sodium bicarbonate, 50 μg/ml pen-
icillin G, 50 μg/ml streptomycin sulfate and 10% fetal 
bovine serum. Cells were cultured at 37℃ in a humidi-
ﬁ ed atmosphere of 5% CO2.  Doxorubicin-treated HL-60 
(HL-60/DOX), which was used as a positive control for 
the expression of MDR1 and MRP1, was maintained 
with 300 ng/ml of DOX28.  Viable cultured cells were 
counted after trypan blue dye exclusion and then as-
sayed by the 3-(4,5-dimethylthiazyl-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) method.  Single cells were 
subcloned in 96-well plates using a limited dilution 
technique (single cell cloning). Single clones were iden-
tiﬁ ed after 2 weeks.  Then, each single colony was iso-
lated by penicillin syringe with trypsinization and sub-
jected to additional single cell cloning twice.  Then, the 
cloned cells were transferred to 24-well plates for ex-
pansion.
2. In vitro model of VCR treatment
 To analyze changes in the sensitivity to VCR, we con-
ducted an in vitro experiment employing a VCR-treat-
ment model that involves continuous incubation at the 
20% inhibitory concentration (IC20) of VCR, in which 
cultured cells could be constantly maintained over 10 
cycles.  This in vitro chemotherapeutic model is based 
on in vivo ﬁ ndings and is equivalent to the in vivo che-
motherapeutic model. Brieﬂ y, 10 ml of cell suspension 
at a concentration of 5× 104 cells/ml in supplemented 
DMEM was seeded on a 90-mm petri dish and incubat-
ed for 24 h.  Culture medium was then exchanged with 
fresh medium containing VCR at IC20.  After 72 h of in-
cubation with VCR, culture medium was replaced with 
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drug-free fresh medium and cells were incubated for an 
additional 72 h.  This 1-week continuous cultivation 
was used as 1 cycle of in vitro chemotherapy (Fig. 1). 
Cells were then subjected to in vitro growth-inhibitory 
assay.
3. In vitro growth-inhibitory activity
 The 50% growth inhibitory concentration (IC50) and 
IC20 of VCR were determined by cultivation in medium 
supplemented with various concentrations of VCR for 
72 h. 
 Exponentially growing cells (2× 103) in 100 μl of me-
dium were seeded on day 0 in 96-well microtiter plates. 
On day one, 100-μl aliquots of medium containing grad-
ed concentrations of VCR were added in triplicate to the 
cell plate.  After incubation at 37℃ in a humidiﬁ ed in-
cubator for 3 days, the plate was washed 3 times with 
PBS.  Then, cell cultures were incubated with 50 μl of 
MTT (1 mg/ml in Dulbecco's PBS) for 4 h at 37℃ on day 
4.  The resulting purple formazan precipitate was solu-
bilized with 200 μl of 0.4 N HCl in isopropanol. Absor-
bance was quantiﬁ ed using a Bio-Rad Model 3550 UV 
microplate reader (Bio-Rad, Hercules, CA) at a test 
wavelength of 570 nm and a reference wavelength of 
630 nm. 
4. Preparation of plasma membrane
 Cells were washed 3 times in PBS followed by centrif-
ugation (400 × g, for 5 min) at 4℃.  The pellet (~2×
107 cells) was resuspended in lysis buffer (10 mM KCl, 
1.5 mM MgCl2, 10 mM Tris - HCl, pH 7.4 at 25℃ and 2 
mM phenylmethyl sulfonyl ﬂ uoride added from a 200 
mM stock solution in 95% ethanol) for 20 min at 4℃, 
and was ruptured using a cell disruption bomb (No. 
4639, Parr Instrument Co., Moline, IL).  The sample 
was centrifuged (4,000 × g for 5 min) to remove cell de-
bris. The remaining supernatant was subjected to high-
speed centrifugation (100,000 × g for 60 min) to yield a 
plasma membrane-enriched, microsomal pellet.  The ﬁ -
nal pellet was resuspended in lysis buffer, and protein 
concentration was determined by bicinchoninic acid as-
say29,30.  
5. Western blot analysis
 Immunoblot analysis was performed as described pre-
viously30.  For analysis of total protein, equal protein 
concentrations from cell extracts were subjected to 7.5% 
SDS-Urea PAGE and were then transferred to Immobi-
lon-P membranes (Millipore Corporation, Bedford, MA). 
Membranes were probed with C219 antibody to detect 
P-glycoprotein or MRPm5 antibody to detect MRP1. 
Proteins were visualized using a horseradish peroxi-
dase-labeled secondary antibody (Zymed, S. San Fran-
cisco, CA) and light-emitting nonradioactive enhanced 
chemiluminescence followed by exposure to autoradio-
graphic ﬁ lm.
6. Xenograft models using cultured carcinoma cell 
lines 
 Female nude mice were subcutaneously injected with 
5× 106 cells from cultured carcinoma cell lines.  When 
tumors grew to approximately 6× 6 mm, which typical-
ly takes about 3 weeks, mice were pair-matched into 
treatment and control groups (day 1).  Each group con-
tained 3 tumor-bearing mice that were ear-tagged and 
followed individually throughout the experiment.  Ad-
ministration of VCR at CED (0.4 mg/kg) began on day 1 
and continued every other day31.  Twice a week the mice 
were weighed and their tumors were measured with 
calipers.  Tumor weight was calculated as follows : 
Weight (mg) = Width (mm)2 × Length (mm)/2
　After 5 weeks of VCR administration, mice were 
weighed and sacriﬁ ced.  Then, tumors were surgically 
excised and subjected to immunohistochemistry.
7. Immunohistochemical detection of MDR1 and 
MRP1 in xenograft tumors
 For immunohistochemical analysis of inoculated tu-
mors in nude mice, we used 1 representative 4-μm sec-
tion from each frozen tumor.  After ﬁ xation with 4% 
Fig. 1　In vitro chemotherapeutic model with VCR (1 cycle)
The cell suspension (10 ml) at a concentration of 5× 104 cells/
ml in DMEM was seeded on a 90-mm petri dish and incubated 
for 24 h. The supernatant was then exchanged with fresh me-
dium containing VCR at IC20. After 72 h of incubation with 
VCR, supernatant was replaced with drug-free fresh medium.
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formaldehyde in PBS for 10 min, preparations were 
washed 3 times with PBS.  After blocking endogenous 
peroxidase activity with 0.3% hydrogen peroxidase-
methanol solution, nonspeciﬁ c conjugation was blocked 
with 5% normal rabbit serum. Slides were incubated 
with C219 monoclonal antibody (Centocore, Marvern, 
PA) (12.5 μg/ml) or MRPm5 monoclonal antibody (Alex-
is Biochemicals, San Diego, CA) (12.5 μg/ml) for 60 min 
at room temperature.  After washing 3 times with PBS, 
slides were incubated at room temperature for 60 min 
with biotinylated anti-mouse IgG rabbit antibody dilut-
ed at 1:2,000.  After incubation with biotinylated anti-
rabbit antibody, slides were washed 3 times with PBS 
and then were incubated with streptavidin coupled to 
horseradish peroxidase (1:500) for 20 min.  All dilutions 
were in PBS with 1% BSA.  Reaction products were vi-
sualized by incubating with 4 mg (v/v) of 3,3'-diamino-
benzidine-tetrahydrochloride (Sigma, St. Louis, MO) 
and 0.02% (v/v) hydrogen peroxide in PBS for 5 min. 
Finally, slides were counterstained with 1% methyl-
green solution. As a negative control, slides were incu-
bated as described above except that the primary anti-
body was replaced with 5% normal rabbit serum. 
8. DOX accumulation and efﬂ ux assay 
 For DOX efﬂ ux studies, cells (1× 106) were incubated 
with 10 mM DOX at 37℃ for 30 min (substrate-loading 
phase) and washed twice with ice-cold PBS.  Thereafter, 
cells were resuspended in DOX-free RPMI1640 in the 
presence or absence of 5μM of cyclosporine or E217βG 
for 60 min.  After incubation, cells were centrifuged and 
washed in ice-cold PBS.  Cell pellets were then resus-
pended in 200 ml of PBS and immediately subjected to 
ﬂ ow cytometric analysis for intracellular DOX reten-
tion.
9. PCR ampliﬁ cation
 Total cellular RNA was isolated from 5× 106 cells us-
ing the standard guanidine isothiocyanate/acid phenol 
method.  First-strand cDNA was then synthesized from 
1 μg of total RNA. Aliquots of synthesized cDNA (corre-
sponding to 200 ng of total RNA) were ampliﬁ ed in 
50-μl reaction mixtures.  The primers are shown in Ta-
ble 1.  The primer sequences for MDR1, MRP1-5, and 
MRP6 were used in previous studies32,33.  The primers 
for MRP7 were designed and synthesized in our labora-
tory using Primer 3 Release 1.0 (Howard Hughes Medi-
cal Institute, Chevy Chase, MD).  The ﬁ nal concentra-
tion of each primer was 0.2 μM. Deoxynucleoside 
triphosphates (0.2 μM each) and 1.5 mM MgCl2 were 
present in the Taq polymerase buffer (Stratagene, La 
Jolla, CA).  PCR cycling for 30 cycles was as follows : de-
naturation at 94℃ for 1 min, primer annealing at 58℃ 
for 1 min, extension at 74℃ for 4 min, and a ﬁ nal po-
Table 1　PCR primers and amplicon sizes
Genes Direction Primer Sequences (5’→ 3’) Amplicon (base pairs)
MDR1
MRP1
MRP2
MRP3
MRP4
MRP5
MRP6
MRP7
GAPDH
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
GGTGCTGGTTGCTGCTTACA
TGGCCAAAATCACAAGGGT
GGACCTGGACTTCGTTCTCA
CGTCCAGACTTCTTCATCCG
CTGCCTCTTCAGAATCTTAG
ATAACCCAAGTTGCAGGCT
CTCAATGTGGCAGACATCGG
GGGAGCTCACAAACGTGTGC
CCATTGAAGATCTTCCTGG
GGTGTTCAATCTGTGTGCA
GGGATAACTTCTCAGTGGGG
GGAATGGCAATGCTCTAAAG
ACACCCATTGGTCACCTGCTA
GGTCACCTGGAGGGCAGCAGAGAC
TAGGTGGGGTGCCAGCCG
TCGGAGGCGCCATCCAGGACT
CGATGCTGGGCGTGAGTAC
CGTTCAGCTCAGGGATGACC
291
292
241
178
240
383
324
367
414
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lymerization at 74℃ for 10 min.  For each PCR, a blank 
control without cDNA was included.  PCR products 
were then separated by electrophoresis on a 1% agarose 
gel. DNA fragments were visualized and photographed 
under UV light after ethidium bromide staining.
10. Statistical analysis
 Data are presented as mean ± S.D. Analysis of vari-
ables was measured using Student's t-test.  Statistical 
signiﬁ cance was set at p<0.05. 
Results
1. VCR-treated HSY cells strongly express MDR1 
and MRP1 when compared with VCR-treated 
SCCSK cells
 To clarify whether MDR1 and MRP1, the 2 best-char-
acterized ABC transporters, are involved in resistance 
to anticancer drugs, we analyzed their expression in 
cultured cell lines by Western blot analysis.  For in vitro 
analysis, the VCR-treated human head and neck cancer 
cell lines SCCSK/VCR and HSY/VCR were established 
from SCCSK and HSY cells by 5 low-dose VCR (IC20) 
treatments (Fig. 1).  The IC20 and IC50 values of antican-
cer drugs in cultured cells are shown in Table 2.  The 
IC50 of SCCSK /VCR and HSY/VCR was signiﬁ cantly in-
creased as compared to parental cells.  In the Western 
blot analysis, DOX-treated HL-60 (HL-60/DOX) cells 
were used as an ABC transporter-positive control cell 
line that strongly expresses both MDR1 and MRP1. 
The staining intensities for MDR1 and MRP1 were 
higher in HSY/VCR cells than in SCCSK/VCR cells (Fig. 
2).
2. Xenograft tumors in VCR-treated nude mice ex-
press MDR1 and MRP1
 On immunohistochemical analysis of inoculated cul-
ture cells in nude mice, SCCSK and HSY cells (with or 
without VCR treatment) were examined using an anti-
MDR1 mAb (C219) and an anti-MRP1 mAb (MRPm5). 
MDR1 and MRP1 expression was observed in the cell 
membranes of SCCSK and HSY tumor cells from VCR-
treated mice, while no expression was observed in tu-
mors from untreated mice (Fig. 3).  Thus, the in vivo 
ﬁ ndings for inoculated culture cells in VCR-treated 
nude mice were similar to the in vitro data on the ex-
pression of MDR1 and MRP1 in SCC/VCR and HSY/
VCR cells as analyzed by Western blots (Fig. 2). 
3. HSY/VCR cells express MRP7 mRNA in addition 
to MDR1 and MRP1 mRNA
 Because speciﬁ c monoclonal antibodies against MRP2 
Table 2　Characteristics of sensitivity to anticancer drugs
Cells
IC20 (nM)a IC50 (nM)a
VCR VCR DOC DOX
SCCSK
SCCSK/VCR
HSY
HSY/VCR
2.8± 0.5
―
5.1± 1.6
―
 4.2± 1.5
 8.4± 1.1b
13.8± 2.6
26.3± 3.8d
 1.0± 0.3
 4.8± 0.9b
 4.2± 0.6
10.3± 2.4d
 5.0± 1.3
 9.6± 1.9b
 5.9± 3.4
15.8± 2.1c
aGrowth inhibitory assay  was determined using MTT assay. Values are 
means± SD of 6 independent experiments. b–dStatistical comparisons were 
performed by the two-tailed Wilcoxon test between parental cell line and 
VCR-treated parental cell (bp<0.05, cp<0.01, dp<0.001). 
Fig. 2　Western blot analysis of cultured cell lines. 
After cultivation of cell lines with or without VCR for 5 cy-
cles, cells were subjected to immunoblot analysis using 
C219 and MRPm5 antibodies. Anti-actin antibody (C-2) 
was used as an internal control.
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through MRP7 were not available, the expression of 
MDR1 and MRP1-7 in cultured cells was analyzed by 
RT-PCR (Fig. 4).  MDR1 mRNA and MRP1 mRNA were 
detected in SCCSK, SCCSK/VCR, HSY and HSY/VCR 
cells.  Furthermore, MRP5 mRNA was detected in SCC-
SK/VCR and HSY/VCR cells, but was barely detectable 
in SCCSK and HSY cells.  Interestingly, MRP7 mRNA 
was expressed in HSY/VCR cells, but was not detected 
in the other cell lines.  SCCSK/VCR cells expressed 
MRP4 mRNA at slightly higher levels than SCCSK 
cells.  Thus, after VCR treatment, SCCSK cells ex-
pressed MRP4 and MRP5, and HSY cells expressed 
MRP5 and MRP7.  
Fig. 3　Immunohistochemical detection of MDR1 and MRP1 in tumor tissues grown in nude mice. 
After administration of VCR for 5 weeks, tumor tissues were excised and immunostained with C219 (for MDR1) 
and MRPm5 (for MDP1) antibodies. The SCCSK/VCR and HSY/VCR tumor cells were excised from mice that re-
ceived VCR for 5 weeks. The SCCSK and HSY tumor cells were excised from mice that received phosphate buff-
ered saline (instead of VCR) for 5 weeks. Bar : 50 μm
Fig. 4　RT-PCR analysis of ABC transporters. 
Total cellular RNA was isolated from 5× 106 cells using 
the standard guanidine isothiocyanate/acid phenol meth-
od. First-strand cDNA was then synthesized from 1 μg of 
total RNA.  cDNA (corresponding to 200 ng of total RNA) 
was ampliﬁ ed in 50-μl reaction mixtures. The primers are 
shown in Table 1. PCR products were separated by electro-
phoresis on a 1% agarose gel. DNA fragments were visual-
ized and photographed under UV light after ethidium bro-
mide staining.
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4. MRP7 mRNA is expressed in VCR-treated HSY 
clones
 Additional experiments were performed to determine 
whether ABC transporter expression is caused by the 
induction of ABC transporter mRNA in intrinsically 
ABC transporter-negative or -undetectable cells or if ac-
tivated production is caused by clonal selection of in-
trinsically ABC transporter-positive cancer cells. Seven 
single cells from the SCCSK and HSY cell lines were 
cloned and subjected to heterogeneity analysis of 
MDR1, MRP1 and MRP7 gene expression by RT-PCR 
(Fig. 5).  Six SCCSK and 5 HSY clones exhibited induc-
tion of MDR1 mRNA, while the remaining cells showed 
activated production of MDR1 mRNA.  Four SCCSK 
clones exhibited induction of MRP1 mRNA, while the 
remaining cells showed activated production of MRP1 
mRNA.  All HSY clones weakly expressed MRP1 mRNA 
and exhibited activated production after VCR treat-
ment.  MRP7 mRNA was heterogeneously induced in 
VCR-treated HSY clone cells.  No expression of MRP7 
was observed in SCCSK clone cells. 
5. Sensitivity of HSY/VCR to docetaxel is in-
creased by E217βG and cyclosporine A
 To clarify whether the drug resistance phenotype is 
caused by ABC transporters, an inhibitory assay of drug 
efﬂ ux in the cultured cell lines was performed using an 
MDR1 and MRP1 inhibitor (cyclosporine A) and an 
MRP7 inhibitor (E217βG).  Although cyclosporine A and 
E217βG are not speciﬁ c inhibitors for ABC transporters, 
they do have comparatively high afﬁ nity to MDR1 and 
MRP1, and MRP7, respectively. Because MRP confers 
resistance to vinca alkaloids and docetaxel, cell cytotox-
icity was measured for cross-resistance using docetaxel. 
Survival of SCCSK/VCR cells cultured with cyclosporine 
A (5 μM) decreased to similar levels as seen in SCCSK 
cells cultured with both cyclosporine A (5 μM) and 
E217βG (5 μM).  On the other hand, HSY/VCR cells 
cultured with cyclosporine A (5 μM) and E217βG (5 
μM) were very sensitive to docetaxel, as compared with 
cells cultured with cyclosporine A (5 μM) alone (Table 3). 
Thus, the sensitivity to an MRP7-related anticancer 
drug, docetaxel, in HSY/VCR cells is restored by treat-
ment with E217βG (Fig. 6). 
6. DOX accumulation is increased in SCCSK/VCR 
and HSY/VCR in the presence of E217βG and cy-
closporine A
 Because MRP7 confers resistance to taxanes (docetaxel 
and paclitaxel) and DOX, we conﬁ rmed DOX accumula-
tion in SCCSK/VCR and HSY/VCR cells by ﬂ ow cyto-
metric analysis. An inhibitor of both MDR1 and MRP1 
(cyclosporine A) increased DOX accumulation in both 
SCC/VCR and HSY/VCR cells (Figs. 7A, B).  However, 
Fig. 5　RT-PCR analysis of MDR1, MRP1 and MRP7 in clone cells. 
Single cells were subcloned in 96-well plates using a limited dilution technique (single cell cloning). 
Single clones were identiﬁ ed after 2 weeks. Then, each single colony was isolated by penicillin sy-
ringe with trypsinization and subjected to additional single cell cloning twice. Then, single cell 
clones were transferred to 24-well plates for expansion. Clone cells were cultured with or without 
VCR treatment (as described in Fig. 1).  Total cellular RNA was isolated from 5× 106 cells using the 
standard guanidine isothiocyanate/acid phenol method. First-strand cDNA was then synthesized 
and from 1 μg of total RNA,  cDNA (corresponding to 200 ng of total RNA) was ampliﬁ ed and PCR 
products were then separated by electrophoresis on a 1% agarose gel. DNA fragments were visual-
ized and photographed under UV light after ethidium bromide staining.
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DOX accumulation was markedly increased in HSY/
VCR cells, but not in SCCSK/VCR cells, in the presence 
of both CsA and E217βG as compared to only CsA (Figs. 
7C, D).  Thus, MRP7 is involved in drug efﬂ ux in HSY/
VCR cells.
Discussion
 The present study has demonstrated that a VCR-
treated SGA cell line, HSY/VCR, expressed MRP7 in ad-
dition to MDR1 and MRP1, whereas no expression of 
MRP7 was observed in an oral VCR-treated SCC cell 
line, SCCSK/VCR.  Furthermore, HSY/VCR exhibited 
cross-resistance to docetaxel.  This differential expres-
sion of ABC transporters in SGA and SCC may be re-
sponsible for the inadequate efﬁ cacy of chemotherapy in 
head and neck cancer.  
Table 3　Cytotoxicity of anticancer drugs with or without inhibitors.
Cells
IC50 (nM)a
VCR DOC DOX
SCCSK/VCR
inhibitor (－)
＋ Cs A
＋ Cs A＋ E217βG
HSY/VCR
inhibitor (－)
＋ Cs A
＋ Cs A＋ E217βG
 8.4± 1.1
 4.9± 1.8b
 4.6± 1.2
26.3± 3.8
19.4± 2.2c
13.8± 1.8f
 4.8± 0.9
 1.1± 0.2b
 1.0± 0.2
10.3± 2.4
 5.9± 1.8c
 2.8± 0.4f
 9.6± 1.9
 6.4± 1.4b
 6.2± 0.6
15.8± 2.1
 8.6± 1.6c
 6.2± 1.8e
aIC50 was determined using MTT assay. Values are means± SD of 6 
independent experiments. b–dStatistical comparisons were performed 
by the two-tailed Wilcoxon test between inhibitor (－) and drug con-
ditions (bp<0.05, cp<0.01, dp<0.001) or between Cs A and drug condi-
tions (ep<0.05, fp<0.01). Cs A : cyclosporin A (5 μM), E217βG:17β-
estradiol-(17-β-D-glucuronide) (5 μM) 
Fig. 6 Restoration of cytotoxic activity in SCCSK/VCR and HSY/VCR cells by modu-
lators, cyclosporine A (CsA) and E217βG. 
After cultivation of SCCSK/VCR and HSY/VCR cells with several concentrations of 
VCR and modulators for 72 h, cytotoxic activity in vitro was determined by trypan blue 
dye exclusion. ＊Signiﬁ cantly different from inhibitor (－ ), as assessed by Student's t 
test (p<0.05). ＊＊Signiﬁ cantly different from cyclosporin A, as assessed by Student's t 
test (p<0.05).
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 Our RT-PCR ﬁ ndings for SCCSK/VCR, HSY/VCR, 
and their parental cell lines suggested that the MDR1 
and MRP1 phenotype is a type of inherent MDR, which 
is derived from clonal selection of intrinsically MDR1- 
or MRP1-positive cancer cells, rather than acquired 
MDR, which is caused by induction of MDR1 or MRP1 
expression in intrinsically MDR1- or MRP1-negative 
cells29.  However, both clones have the potential to ex-
hibit heterogeneous induction and production of MDR1 
and MRP1 mRNA.  Thus, the interpretation of the RT-
PCR data may not be adequate to explain the acquisi-
tion of MDR.  Moreover, expression of MRP7 was ob-
served in HSY/VCR cells but not in SCCSK/VCR cells. 
Thus, when compared with SCC, SGA exhibits induc-
tion and activated production of MDR1, MRP1 and 
MRP7, leading to potent MDR against anticancer drugs. 
These suggestive results were based on the study of 
only 7 cloned cells derived from SCCSK and HSY cells. 
A ﬂ uctuation test should be performed with more cloned 
cells and other head and neck cell lines to validate this 
evidence.  
 In the present study, MRP4 was weakly expressed in 
SCCSK cells and strongly expressed in SCCSK/VCR 
cells.  However, HSY and HSY/VCR cells did not ex-
press MRP4, while both cell types expressed MRP5. 
These results suggest that MRP4 expression is a char-
acteristic of oral SCC cells.  MRP members can be struc-
turally classiﬁ ed according to the presence of an N-ter-
minal membrane-spanning domain34.  This topological 
feature is expressed in MRP1, MRP2, MRP3, MRP6 and 
Fig. 7　Flow cytometric analysis of DOX efﬂ ux in SCCSK/VCR and HSY/VCR cells.
CsA: cyclosporine A (5 μM), E217βG: 17β-estradiol 17-(β-D-glucuronide) (5 μM).
For DOX efﬂ ux studies, cells (1× 106) were incubated with 10 mM DOX at 37℃ for 30 min (sub-
strate-loading phase) and washed twice with ice-cold PBS. Thereafter, cells were resuspended in 
DOX-free RPMI1640 in the presence or absence of 5 μM of CsA or E217βG for 60 min. After incuba-
tion, cells were centrifuged and washed in ice-cold PBS. Cell pellets were then resuspended in 200 
ml of PBS and immediately subjected to ﬂ ow cytometric analysis for intracellular DOX retention.
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MRP7, but is absent in MRP4 and MRP535.  In addition, 
MRP1, MRP2, MRP3 and MRP6 confer resistance to 
natural product agents6, in contrast to MRP4 and 
MRP5, which confer resistance to nucleotide analogs18,36. 
Thus, induction of MRP7 mRNA in HSY/VCR cells sug-
gests that combined chemotherapy for head and neck 
cancers would exhibit insufﬁ cient clinical outcome, par-
ticularly in SGA when compared with SCC.
 MRP7 has 3 membrane-spanning domains and pos-
sesses the cardinal biochemical feature of the MRP fami-
ly, the ability to transport amphipathic anions such as 
E217G, an inhibitor of MRP3, MRP6 and MRP715,18,21,25,37. 
In the present study, HSY/VCR did not express MRP3 
or MRP6, suggesting that E217G-mediated inhibition of 
MRP7 is involved in the increased sensitivity of HSY/
VCR to docetaxel. 
 The majority of salivary gland tumors contain 2 
distinct populations of tumor cells, luminal cells and 
abluminal cells.  Abluminal cells demonstrate the most 
heterogeneous cellular differentiation38.  Hence, the dif-
ferent types of salivary gland tumors can exhibit vari-
able levels of MDR1 and MRP1 expression, as well as 
cellular differentiation.  Disparities in the expression of 
MDR1 and MRP1 could also be derived from the hetero-
geneous populations of clone cells as a consequence of 
inherited, acquired or activated production of MDR1 
and MRP1.  However, it has been difﬁ cult to determine 
whether clonal selection or the acquisition or activated 
production of MDR1 and MRP1 causes the observed 
MDR phenotype.
 Because previous ﬁ ndings from in vivo experiments 
were subsequent to clonal selection of drug-resistant 
phenotypes, it is difﬁ cult to conﬁ rm which MDR1 or 
MRP1 expression process is involved in drug resistance. 
On the other hand, the stepwise sequential exposure to 
increasing concentrations of anticancer drugs in vitro 
has previously been used to establish MDR1- and 
MRP1-expressing cells using variant cell lines that ex-
press high levels of MDR1 and MRP1.  Despite the im-
portance of characterizing transporter function, these 
experiments are unsuitable for clinical settings and for 
clarifying whether ABC transporters play a functional 
role in the failure of initial chemotherapy or whether 
MDR is caused by the development of intrinsic or ac-
quired resistance.  Clinically, two-fold resistance to an-
ticancer drugs suggests a difﬁ culty in overcoming che-
motherapeutic cancer treatments due to their toxicity in 
a living body.  Thus, it is necessary to analyze the pro-
gression of ABC transporter mediated-MDR phenotypes 
with CED in both in vivo and in vitro studies.  In the 
present study, we determined VCR concentrations for in 
vitro drug-resistance analysis based on an in vivo che-
motherapeutic model using CED.  The combination of in 
vitro and in vivo studies was useful in determining drug 
concentrations for clinical observations and is suitable 
for in vitro drug-resistance assays.
 Recent studies have focused on investigating the role 
of MDR1 and MRP1 in acquired drug resistance by 
measuring levels at diagnosis and at relapse after treat-
ment with MDR-related drugs39–41.  Kelley et al. report-
ed a correlation between MDR1 expression and re-
sponse to chemotherapy in SCC of the head and neck42. 
They concluded that analyzing the expression of MDR1 
may be useful when planning the chemotherapeutic 
regimens for patients with head and neck cancer and 
that MDR1 expression may be an additional prognostic 
and diagnostic tool in these patients.  Robey-Caffery et 
al. suggested that clinical response is correlated with 
expression of MDR1 in adenocarcinoma41.  Filipits et al. 
reported that MRP1 may be a useful marker for select-
ing appropriate adjuvant therapy in patients with early-
stage breast cancer after prospective conﬁ rmatory eval-
uation42.  As in previous studies, the present study 
demonstrated the expression of MDR1 and MRP1 in 
SCC and SGA.  The IC50 of VCR, DOC and DOX was 
also higher in the presence of MDR1 and MRP1 expres-
sion.  Our ﬁ ndings support the notion that MDR1 and 
MRP1 are useful in evaluating potential MDR.  Howev-
er, inherently MDR1- and MRP1-negative clone cells ca-
pable of inducing high levels of MDR1 and MRP1 ex-
pression were barely detected by immunohistochemistry 
and RT-PCR; these results suggest that MDR1 and 
MRP are not sufﬁ cient predictive markers of MDR phe-
notypes, such as SGA. 
 In conclusion, the present study indicates that MDR1- 
and MRP1-related MDR in SGA is an inherent pheno-
type caused by high levels of MDR1 and MRP1 induc-
tion and activated production based on clonal selection 
during VCR treatment.  Moreover, HSY/VCR cells ex-
pressed MRP7, in addition to MDR1 and MRP1, and ex-
hibited cross-resistance to docetaxel.  In contrast, MRP7 
expression was not seen in SCCSK/VCR cells.  This dif-
ferential expression of ABC transporters may inﬂ uence 
MDR.  These ﬁ ndings are consistent with the previous 
82 Oral Science International　Vol. 3, No. 2
clinical ﬁ nding that SGA exhibits severe cross-resis-
tance to anticancer drugs when compared with SCC.
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